21 November 2017
News and Views
Links and Services
Trough serum infliximab is a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis, reports January's issue of Gut.
Antibodies to infliximab reduce serum infliximab with loss of clinical benefit.
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors